5A1MQ
Small-molecule NNMT inhibitor that reduced body weight and white fat mass in diet-induced obese mice. Proposed to act by raising intracellular NAD+ and SAM (shown in cultured adipocytes).
Regulatory status (as of Sept 2026)
Not FDA-approved. Not among the peptides named in the 2026 PCAC actions.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
5-Amino-1MQ is a compound studied only in animals and lab experiments so far. Small-molecule NNMT inhibitor that reduced body weight and white fat mass in diet-induced obese mice.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Oral |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsDiet-induced obese mice given the NNMT inhibitor systemically (by injection) (Neelakantan 2017); the exact mg/kg is in the full text, not the abstract. The study also used cultured adipocytes, and a 2022 DIO-mouse study combined it with a low-fat diet. No human dosing has been published.Community-reportedCommunity-reported: 50–150 mg oral, oral |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is thought to work by blocking an enzyme (NNMT) involved in fat-cell metabolism; this has only been studied in mice and cells. Proposed mechanism, from mouse and cell studies: inhibition of the enzyme nicotinamide N-methyltransferase (NNMT). Small-molecule NNMT inhibitors reversed high-fat-diet-induced obesity in mice (Neelakantan 2018), and 5-amino-1MQ combined with a low-fat diet reduced adiposity and body weight in diet-induced obese mice (Dimet-Wiley 2022).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedUsers have reported doses of 50–150 mg (oral). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| 5-Amino-1MQ | Unknown | Oral | Preclinical (animal) |
| AOD-9604 | No published PK data found | Subcutaneous injection | Discontinued |
| Adipotide (FTPP) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| Dulaglutide | ~5 days | Subcutaneous injection | FDA-approved |
| Exenatide | 2.4 hours (immediate-release) | Subcutaneous injection | FDA-approved |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Metabolic category. View All Metabolic Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.